Fundraising Fox

Genomenon

Ann Arbor, US · Founded 2014 · Delaware corporation · 6 known investors

genomenon.com ↗

Genomenon uses purpose-built AI combined with expert scientific curation to index and structure real-world evidence from millions of biomedical articles, including full text, tables, figures, and supplemental data. Its products Mastermind and the Cancer Knowledgebase serve clinical diagnostic labs and biopharmaceutical drug programs to interpret genetic variants, support diagnoses, and inform drug development decisions.

AI & Machine LearningBiotechDigital Healthin /genomenon@genomenon

Founders & leadership

ES
Eli SalembierExecutive Officer, Director
MK
Mark KielExecutive Officer, Director
SS
Sonya SepahbanDirector
MK
Michael KleinExecutive Officer, Director
PG
Patricia GlazaDirector
DG
David GregorkaDirector
MG
Michael GrossDirector
BG
Brian GroarkExecutive Officer
SG
Sam GlobusExecutive Officer
DS
Dr. Sam GlobusChief Operating Officer

Investors · 6

BeringeaLondon · $3M – $10M
Green Park & Golf VenturesDallas · $500K – $2M
ID VenturesDetroit · $50K – $250K
Invest MichiganNorthville · $100K – $250K
IrishAngelsSan Francisco · $250K – $350K
Michigan RiseEast Lansing · $50K – $150K

Reported raises · per SEC filings

Form D private placements
▶$6MraisedJul 2026 · 30 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Michael KleinExecutive Officer, Director
  • Mark KielExecutive Officer, Director
  • Patricia GlazaDirector
  • David GregorkaDirector
  • Michael GrossDirector
  • Brian GroarkExecutive Officer
  • Sam GlobusExecutive Officer
Offering amount
$10M
Amount sold
$6M
First sale
Jul 2026
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$5.5MraisedMay 2024 · 30 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Mark KielExecutive Officer, Director
  • Patricia GlazaDirector
  • Michael KleinExecutive Officer, Director
  • David GregorkaDirector
  • Michael GrossDirector
  • Sam GlobusExecutive Officer
  • Sean KearneyExecutive Officer
Offering amount
$6M
Amount sold
$5.5M
First sale
May 2024
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$20MraisedMar 2022 · 23 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Michael KleinExecutive Officer, Director
  • David GregorkaDirector
  • Patricia GlazaDirector
  • Michael GrossDirector
  • Mark KielExecutive Officer, Director
Offering amount
$20M
Amount sold
$20M
First sale
Feb 2022
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2.9MraisedMay 2020 · 36 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Mark KielExecutive Officer, Director
  • Michael KleinExecutive Officer, Director
  • David GregorkaDirector
  • Steve SchwartzExecutive Officer
  • Patricia GlazaDirector
  • Charles MoretDirector
Offering amount
$3M
Amount sold
$2.9M
First sale
May 2020
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$446KraisedAug 2015 · 11 investors · Computers
Rule 506(b)
Officers, directors & promoters on the filing
  • Eli SalembierExecutive Officer, Director
  • Mark KielExecutive Officer, Director
  • Sonya SepahbanDirector
Offering amount
$1M
Amount sold
$446K
First sale
Aug 2015
Incorporated
Corporation, Delaware, 2014
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.